Evaluation of clinical profiles, imaging findings and antituberculosis treatment outcome in granulomatous mastitis : An Indian scenario
Copyright © 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved..
BACKGROUND: The management of choice for granulomatous mastitis (GM) has yet to be determined but few studies have demonstrated that anti-tubercular treatment (ATT) could be an effective alternative therapeutic option. Hence, the objective of the current study is to determine the clinical feature, radiological imaging findings, and histopathological examination results exhibited by GM and tuberculosis (TB)-proven GM as well as to evaluate the ATT clinical outcome in GM patients.
METHODS: The study was performed on 68 GM patients who were referred to the department of pulmonology by the breast clinic (from January 2018 to August 2021). Study populations were categorized into two groups GM and TB-proven GM patients and all were prescribed with standard ATT regimen and were continuously followed up. SPSS version 25 was employed for statistical assessment.
RESULTS: Our study showed that 6 patients from GM and 4 patients from the TB-proven GM group got relapsed. For patients who displayed partial remission, ATT treatment was started after assessing the side effects potential. 14.6% (n = 6) and 7.4% (n = 2) patients who initially demonstrated partial remission were also completely cured. ATT treatment curable rate was determined to be 90% (n = 37) and 81.5% (n = 22) for GM and TB-proven GM patients correspondingly. Therefore, the current study demonstrated nil significant differences between groups.
CONCLUSION: The current study warrants that ATT therapy could be an effective and better treatment of choice for GM patients irrespective of their clinical condition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
The Indian journal of tuberculosis - 71(2024), 2 vom: 08. Apr., Seite 163-169 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mithen, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-tubercular treatment |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijtb.2023.04.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370784693 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370784693 | ||
| 003 | DE-627 | ||
| 005 | 20240410232939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijtb.2023.04.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370784693 | ||
| 035 | |a (NLM)38589120 | ||
| 035 | |a (PII)S0019-5707(23)00082-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mithen, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of clinical profiles, imaging findings and antituberculosis treatment outcome in granulomatous mastitis |b An Indian scenario |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: The management of choice for granulomatous mastitis (GM) has yet to be determined but few studies have demonstrated that anti-tubercular treatment (ATT) could be an effective alternative therapeutic option. Hence, the objective of the current study is to determine the clinical feature, radiological imaging findings, and histopathological examination results exhibited by GM and tuberculosis (TB)-proven GM as well as to evaluate the ATT clinical outcome in GM patients | ||
| 520 | |a METHODS: The study was performed on 68 GM patients who were referred to the department of pulmonology by the breast clinic (from January 2018 to August 2021). Study populations were categorized into two groups GM and TB-proven GM patients and all were prescribed with standard ATT regimen and were continuously followed up. SPSS version 25 was employed for statistical assessment | ||
| 520 | |a RESULTS: Our study showed that 6 patients from GM and 4 patients from the TB-proven GM group got relapsed. For patients who displayed partial remission, ATT treatment was started after assessing the side effects potential. 14.6% (n = 6) and 7.4% (n = 2) patients who initially demonstrated partial remission were also completely cured. ATT treatment curable rate was determined to be 90% (n = 37) and 81.5% (n = 22) for GM and TB-proven GM patients correspondingly. Therefore, the current study demonstrated nil significant differences between groups | ||
| 520 | |a CONCLUSION: The current study warrants that ATT therapy could be an effective and better treatment of choice for GM patients irrespective of their clinical condition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-tubercular treatment | |
| 650 | 4 | |a Clinical features | |
| 650 | 4 | |a Fine needle aspiration for cytology | |
| 650 | 4 | |a Granulomatous mastitis | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Mahin Nallasivam, R R |e verfasserin |4 aut | |
| 700 | 1 | |a Thangaswamy, Dhanasekar |e verfasserin |4 aut | |
| 700 | 1 | |a Mohanapriya, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Indian journal of tuberculosis |d 2007 |g 71(2024), 2 vom: 08. Apr., Seite 163-169 |w (DE-627)NLM169864154 |x 0019-5707 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2024 |g number:2 |g day:08 |g month:04 |g pages:163-169 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijtb.2023.04.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2024 |e 2 |b 08 |c 04 |h 163-169 | ||